| abstract |
The present invention relates to novel nucleoside and nucleoside analog monoester derivatives of formula (I), to their preparation and to antiviral pharmaceutical compositions containing them, as well as to the preparation thereof. In formula (I), Fa is? -9 monounsaturated acyl group derived from a C18 or C20 fatty acid esterified with a 5'-hydroxyl group of the sugar moiety of the nucleoside or a hydroxyl group on the non-cyclic chain of the nucleoside analog, and Nu is a group of formula (II) wherein Z is 1. ribofuranosyl or arabinofuranosyl, their 2- and / or 3-position deoxy derivatives, 3-azido derivatives of 3- and 2,3-deoxy derivatives, and 2-hydroxyethoxymethyl, 4-hydroxy-3- (hydroxy) methyl) butyl, 2-hydroxy-1- (hydroxymethyl) ethoxymethyl or 2,3-dihydroxypropyl, and B is adenyl, guanyl, cytosinyl, uracilyl or vytiminyl, mono- or di (C1-C6) -alkylated derivatives thereof, where the coupling takes place in the 1-position in the case of pyrimidine bases and in the 9-position in the case of purine bases, provided that the 5'-O-ol 1-aracytidine, 5'-O-elaidoyl-N6, N6-dimethyladenosine and 5'-O-oleyl-N6, N6-dimethyladenosine are excluded from the scope of protection. The oleyl, elaidoyl and cis-trans-eicosanoyl esters of the present invention have outstanding antiviral activity. ŕ |